Version 2- Bladder Utility Symptoms Scale - P (BUSS-P)
- 技術應用
- Patient HRQOL assessment Patient-reported outcome
- 詳細技術說明
- An innovative clinical instrument to measure health-related quality of life among Bladder Cancer patients
- *Abstract
-
Overview:
Health-related quality of life (HRQOL) is importantin bladder cancer care and clinical decision-making because patients mustchoose between diverse treatment modalities with unique morbidities. Apatient-reported outcome (PRO) measure of overall HRQOL for bladder cancer,regardless of disease severity and treatment, could benefit clinical care andresearch.
Materials and Methods:
Prospective questionnaire development was completedin three parts. In study 1, the Bladder Utility Symptom Scale-Psychometric(BUSS-P) questions were created by experts using a conceptual framework of BCHRQOL items generated through patient focus groups. In study 2, BC patients(n=112), including those treated with surgery, radiation and chemotherapy,completed the BUSS-P and five HRQOL instruments at baseline and four weeks laterto assess validity and test-retest reliability. External validity was thenexplored in study 3 by administering the BUSS-P to 578 patients online and atclinics. Construct validity was assessed with whole and subscale Spearman’srank correlations and comparisons of BUSS-P scores across known-groups.
Results:
The BUSS-P had high whole-scale correlation with theFACT-Bl (rs=0.82, p<0.0001) and substantial-to-high subscale correlationswith the EQ-5D-3L (e.g. emotional wellbeing: rs=0.69, p<0.0001). BUSS-Pscores were lower for patients with comorbidity and advanced disease. Cognitivedebriefing and 94% completion rate suggested good comprehensibility. There wasexcellent test-retest reliability (intraclass correlation coefficient = 0.79).Limitations include extended time from diagnosis in many patients.
Conclusion:
The BUSS-P is a reliable and valid PRO instrumentfor HRQOL among all bladder cancer patients, regardless of treatment receivedor stage of disease.
- *Principal Investigation
-
- Dr. Girish Kulkarni, Dr. Murray Krahn, Dr. Nathan Perlis, Dr. Shabbir Alibhai
- *Publications
- Perlis N, Krahn M,Boehm E K, Alibhai S, Jamal M, Finelli A, Sridhar S, Chung P, Gandhi R, JonesJ, Tomlinson G, Bremner K, Kulkarni G. TheBladder Utility Symptom Scale (BUSS): A Novel Patient-Reported OutcomeInstrument in Bladder Cancer. Journal ofUrology Published online: March 09, 2018.Perlis N, Krahn M, Alibhai S, Finelli A, Ritvo P,Bremner K, Kulkarni G. Conceptualizingglobal health-related quality of life in bladder cancer. Qual Life Res. 2014Oct;23(8):2153-67Perlis N, Boehme K, Jamal M, Bremner K, Alibhai S, Finelli A,Ritvo P, Krahn M, Gandhi R, Kulkarni G. MP31-17Validating the Bladder Utility Symptom Scale (BUSS): A Novel Patient ReportedOutcome Quality Of Life Measure for All Patients with Bladder Cancer.Journal of Urology April 2016 Volume 195, Issue 4, Supplement, Page e426PerlisN, Kulkarni G, Finelli A, Krahn K, Naimark D. MP15-02 ComparingRadical Cystectomy with and without Neoadjuvant Chemotherapy to RadiationTherapy-Based Bladder Conservation Approaches for Muscle-Invasive BladderCancer: A Decision Analysis. Journal of Urology April 2014 Volume 191, Issue 4, Supplement, Page e144Perlis N, Krahn M, Alibhai S, Finelli A, RitvoP, Bremner K, Boehme K, Kulkarni G.MP15-01Developing the Bladder Utility Symptom Scale: A Multi-attribute Health StateClassification for Bladder Cancer. Journal of UrologyApril 2014Volume 191, Issue 4, Supplement, Page e144
- 國家/地區
- 美國
